Biogen's $7.3B M&A deal, layoffs; R&D shakeup at Pfizer, AstraZeneca; Scaling rare disease meds; Q2 earnings; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
The Endpoints newsroom is continuing to grow! Reynald Castañeda joined us this week from London — he will lead two other UK colleagues, Ayisha Sharma and Anna Brown, in beefing up our early morning reporting. On the US side, Lydia Ramsey Pflanzer will be spearheading the expansion of our coverage into health tech. If you missed it, read Drew Armstrong’s note for more.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.